Related Experiment Video
Updated: Jun 4, 2025
12:43
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
11.8K
Reprogramming Dysfunctional Dendritic Cells by a Versatile Catalytic Dual Oxide Antigen-Captured Nanosponge for
Min-Ren Chiang1, Chin-Wei Hsu1, Wan-Chi Pan1
1Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 300044, Taiwan.
ACS Nano
|December 31, 2024
Summary
A novel dual catalytic oxide nanosponge (DON) reprograms immunosuppressive dendritic cells (DCs) for enhanced cancer immunotherapy. This DON-based therapy, combined with anti-PD1, effectively suppresses tumors and improves survival in lung metastases.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunotherapy
Background:
- Dendritic cells (DCs) are crucial for initiating antitumor immune responses but are often functionally impaired within the tumor microenvironment.
- Tumor-associated immunosuppression hinders DC antigen presentation and limits effective anti-cancer immunity.
Purpose of the Study:
- To develop a dual catalytic oxide nanosponge (DON) capable of remotely boosting catalytic activity and reprogramming DCs for enhanced cancer immunotherapy.
- To investigate the efficacy of DON in combination with anti-PD1 therapy for suppressing lung metastases and improving survival.
Main Methods:
- Intravenous delivery of DON for enhanced tumor accumulation.
- DON utilizes cerium oxide nanozyme-coated iron oxide nanocubes for chemodynamic therapy (CDT) via ROS generation and glutathione depletion.
- High-frequency magnetic field (HFMF) irradiation to boost DON's catalytic activity and promote antigen release.
- DON acts as a porous antigen transporter to deliver tumor-associated antigens to DCs, stimulating immune responses.
Main Results:
- HFMF-boosted DON effectively promotes ROS generation and antigen release from tumors.
- DON successfully programs DCs, leading to sustained immune stimulation.
- Combination therapy of DON and anti-PD1 significantly suppressed lung metastases and improved survival beyond 40 days.
Conclusions:
- The DON system offers a promising strategy for overcoming tumor-induced immunosuppression by reprogramming dendritic cells.
- This dual catalytic nanosponge platform demonstrates significant potential for enhancing cancer immunotherapy efficacy, particularly in combination with immune checkpoint inhibitors.
